VivoSeq
Infectious Disease

Cytomegalovirus Disease

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Cytomegalovirus Disease is an early-stage landscape with 0 programs across 2 companies. The most active players are Roche, Jazz Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalJazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Terminated1 · 17%
Unknown status1 · 17%

Clinical Trials

Trial Activity

6 trials

A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
Completed·Roche logoRoche·Phase 2·NCT01753167·122 enrolled
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Completed·Roche logoRoche·Phase 3·NCT00294515·326 enrolled
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
Completed·Roche logoRoche·N/A·NCT00002025
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001038·1,200 enrolled
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
Terminated·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT02439970·5 enrolled
Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Unknown status·—·Phase 2·NCT00828503·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)